Next Day Disclosure Return
Filed with HKEX · Stock code 6938 · · 6 pages · English
Suzhou Ribo Life Science Co. Ltd. on 6ix
Earlier from Suzhou Ribo Life Science
- Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
- Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
- Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
Later from Suzhou Ribo Life Science
- 2026 Interim report
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - phase i clinical trial application submission of RBD3133 injection for overweight and obesity
- Discloseable and connected transaction acquisition of the remaining 49.71% shareholding in a subsidiary involving the issue of consideration shares under Specific mandate; and proposed change of registered capital and amendments to the articles of association
Follow Suzhou Ribo Life Science into a list and get an email when it puts out news.
Follow Suzhou Ribo Life Science